Tapentadol hydrochloride: A next-generation, centrally acting analgesic with two mechanisms of action in a single molecule

Drugs of Today

Volumn 45, Issue 7, 2009, Pages 483-496

  Tzschentke, Thomas M ^a   Jahnel, Ulrich ^a   Kögel, Babette ^a   Christoph, Thomas ^a   Englberger, Werner ^a   De Vry, Jean ^a   Schiene, Klaus ^a   Okamoto, Akiko ^b   Upmalis, David ^b   Weber, Horst ^a   Lange, Claudia ^a   Stegmann, Jens Ulrich ^a   Kleinert, Regina ^a  

^a GRÜNENTHAL GMBH   (Germany)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; HYDROCODONE BITARTRATE PLUS IBUPROFEN; MORPHINE; MU OPIATE RECEPTOR; NORADRENALIN UPTAKE INHIBITOR; OXYCODONE; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; PLACEBO; TAPENTADOL; TYLENOL WITH CODEINE; UNCLASSIFIED DRUG;

ANALGESIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFLAMMATION; MONONEUROPATHY; NAUSEA; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PATIENT COMPLIANCE; POLYNEUROPATHY; PRURITUS; REVIEW; SOMNOLENCE; VISCERAL PAIN; VOMITING; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANALGESICS; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; PAIN; PHENOLS; RECEPTORS, OPIOID, MU;

EID: 71249138937     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.7.1395291     Document Type: Review

References (60)

1. Freynhagen, R., Baron, R., Gockel, U., Tolle, T.R. painDETECT: A new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006, 22(10): 1911-1920 (Pubitemid 44663395)
2. McDonald, A.A., Portenoy, R.K. How to use antidepressants and anticonvulsants as adjuvant analgesics in the treatment of neuropathic cancer pain. J Support Oncol 2006, 4(1): 43-52.
3. Maizels, M., McCarberg, B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician 2005, 71(3): 483-490 (Pubitemid 40194067)
4. Moore, R.A., McQuay, H.J. Prevalence of opioid adverse events in chronic non-malignant pain: Systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005, 7(5): R1046-R1051.
5. Andersohn, F., Suissa, S., Garbe, E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006, 113(16): 1950-1957 (Pubitemid 43754197)
6. Towheed, T.E., Maxwell, L. Acetaminophen for osteoarthritis (Review). Cochrane Database Syst Rev 2006, (1): CD004257.
7. Wolfe, M.M., Lichtenstein, D.R., Singh, G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999, 340(24): 1888-1899 (Pubitemid 29272670)
8. Friderichs, E., Buschmann, H. Opioids with clinical relevance. In: Analgesics - from chemistry and pharmacology to clinical application. Buschmann, H., Christoph, T., Friderichs, E., Maul, C., Sundermann, B. (Eds.). Wiley-VCH: Weinheim, Germany 2002, 171-245.
9. Curatolo, M., Sveticic, G. Drug combinations in pain treatment: a review of the published evidence and a method for finding the optimal combination. Best Pract Res Clin Anaesthesiol 2002, 16(4): 507-519 (Pubitemid 38937100)
10. Smith, H.S. Combination opioid analgesics. Pain Physician 2008, 11(2): 201-214
11. Raffa, R.B., Friderichs, E., Reimann, W., Shank, R.P., Codd, E.E., Vaught, J.L. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992, 260(1): 275-285
12. Epstein, D.H., Preston, K.L., Jasinski, D.R. Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: Lessons from tramadol. Biol Psychol 2006, 73(1): 90-99
13. Radbruch, L., Grond, S., Lehmann, K.A. A risk-benefit assessment of tramadol in the management of pain. Drug Saf 1996, 15(1): 8-29. (Pubitemid 26248755)
14. Tzschentke, T.M., De Vry, J., Terlinden, R., et al. Tapentadol HCl. Drugs Future 2006, 31(12): 1053-1061
15. Tzschentke, T.M., Christoph, T., Kögel, B., et al. (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): A novel m opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007, 323(1): 265-276
16. Monory, K., Greiner, E., Sartania, N., et al. Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinans. Life Sci 1999, 64(22): 2011-2020 (Pubitemid 29236584)
17. Millan, M.J. Descending control of pain. Prog Neurobiol 2002, 66(6): 355-474.
18. Max, M.B., Lynch, S.A., Muir, J., Shoaf, S.E., Smoller, B., Dubner, R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992, 326(19): 1250-1256
19. Staiger, T.O., Gaster, B., Sullivan, M.D., Deyo, R.A. Systematic review of antidepressants in the treatment of chronic low back pain. Spine 2003, 28(22): 2540-2545 (Pubitemid 37448972)
20. Raffa, R.B., Friderichs, E. The basic science aspect of tramadol hydrochloride. Pain Rev 1996, 3249-3271
21. Alván, G., Bechtel, P., Iselius, L., Gundert-Remy, U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990, 39(6): 533-537
22. Poulsen, L., Arendt-Nielsen, L., Brosen, K., Sindrup, S.H. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996, 60(6): 636-644 (Pubitemid 27025910)
23. Klotz, U. Tramadol - the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneimittelforschung 2003, 53(10): 681-687 (Pubitemid 37357353)
24. Koren, G., Cairns, J., Chitayat, D., Gaedigk, A., Leeder, S.J. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006, 368(9536): 704.
25. Mikus, G., Weiss, J. Influence of CYP2D6 genetics on opioid kinetics, metabolism and response. Curr Pharmacogenomics 2005, 3(1): 43-52. (Pubitemid 40352698)
26. Nagar, S., Raffa, R.B. Looking beyond the administered drug: metabolites of opioid analgesics. J Fam Pract 2008, 57(suppl 6A): S1-S8.
27. Desmeules, J.A., Piguet, V., Collart, L., Dayer, P. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol 1996, 41(1): 7-12. (Pubitemid 26009905)
28. Desmeules, J.A., Violand, C., Piguet, V., Kondo-Oestreicher, M., Cheseaux, N., Dayer, P. The mixed analgesic effects of tramadol enantiomers. Clin Pharmacol Ther 1999, 65: 121.
29. Oliva, P., Aurilio, C., Massimo, F., et al. The antinociceptive effect of tramadol in the formalin test is mediated by the serotonergic component. Eur J Pharmacol 2002, 445(3): 179-185
30. Suzuki, R., Rygh, L.J., Dickenson, A.H. Bad news from the brain: Descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci 2004, 25(12): 613-617 (Pubitemid 39458166)
31. Suzuki, R., Rahman, W., Hunt, S.P., Dickenson, A.H. Descending facilitatory control of mechanically evoked responses is enhanced in deep dorsal horn neurones following peripheral nerve injury. Brain Res 2004, 1019(1-2): 68-76.
32. Sommer, C. Is serotonin hyperalgesic or analgesic? Curr Pain Headache Rep 2006, 10(2): 101-106
33. Bhandari, P., Bingham, S., Andrews, P.L. The neuropharmacology of loperamide-induced emesis in the ferret: The role of the area postrema, vagus, opiate and 5-HT3 receptors. Neuropharmacology 1992, 31(8): 735-742
34. Porreca, F., Ossipov, M.H. Nausea and vomiting side effects reduce the efficiency of opioid analgesics. Pain Med 2008, in press.
35. Tyers, M.B., Freeman, A.J. Mechanism of the anti-emetic activity of 5-HT3 receptor antagonists. Oncology 1992, 49(4): 263-268
36. Friedman, D.P. Perspectives on the medical use of drugs of abuse. J Pain Symptom Manage 1990, 5(1 Suppl): S2-S5. (Pubitemid 20156193)
37. Williams, J.T., Christie, M.J., Manzoni, O. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 2001, 81(1): 299-343.
38. Aghajanian, G.K. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature 1978, 276(5684): 186-188
39. Cruz, H.G., Berton, F., Sollini, M., Blanchet, C., Pravetoni, M., Wickman, K., Luscher, C. Absence and rescue of morphine withdrawal in GIRK/Kir3 knock-out mice. J Neurosci 2008, 28(15): 4069-4077
40. Svensson, I., Sjostrom, B., Haljamae, H. Influence of expectations and actual pain experiences on satisfaction with post-operative pain management. Eur J Pain 2001, 5(2): 125-133 (Pubitemid 32705993)
41. Gureje, O., Von, K.M., Simon, G.E., Gater, R. Persistent pain and well-being: A world health organization study in primary care. JAMA: The Journal of the American Medical Association 1998, 280(2): 147-151 (Pubitemid 28498386)
42. Gan, T.J., Lubarsky, D.A., Flood, E.M., Thanh, T., Mauskopf, J., Mayne, T., Chen, C. Patient preferences for acute pain treatment. Br J Anaesth 2004, 92(5): 681-688
43. Daniels, S.E., Upmalis, D., Okamoto, A., Lange, C., Häeussler, J. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009, 25(3): 765-776
44. Hale, M., Upmalis, D., Okamoto, A., Lange, C., Rauschkolb, C. Long-term safety and tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee: a randomized, double-blind study. Curr Med Res Opin 2009, in press.
45. Hartrick, C., Van Hove, I., Stegmann, J.-U., Oh, C., Upmalis, D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 2009, 31(2): 260-271
46. Stegmann, J.-U., Weber, H., Steup, A., Okamoto, A., Upmalis, D., Daniels, S. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr Med Res Opin 2008, 24(11): 3185-3196
47. Lange, C., Steup, A., Black, P., Desjardins, P. Analgesic efficacy and tolerability of tapentadol, a new centrally acting analgesic following bunionectomy. Poster presented at: 8th European Federation of National Associations of Orthopaedics and Traumatology, 11-15 May 2007, Florence, Italy.
48. Ford, L.B. Soft-tissue bunionectomy in podiatric surgery. Clin Podiatr Med Surg 1991, 8(1): 63-70.
49. Thipphawong, J.B., Babul, N., Morishige, R.J., Findlay, H.K., Reber, K.R., Millward, G.J., Otulana, B.A. Analgesic efficacy of inhaled morphine in patients after bunionectomy surgery. Anesthesiology 2003, 99(3): 693-700.
50. Avouac, J., Gossec, L., Dougados, M. Efficacy and safety of opioids for osteoarthritis: A meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2007, 15(8): 957-65.
51. Jordan, K.M., Arden, N.K., Doherty, M., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62(12): 1145-1155
52. Markenson, J.A., Croft, J., Zhang, P.G., Richards, P. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain 2005, 21(6): 524-535 (Pubitemid 41527742)
53. Veves, A., Backonja, M., Malik, R.A. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med 2008, 9(6): 660-674
54. Gimbel, J.S., Richards, P., Portenoy, R.K. Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology 2003, 60(6): 927-934 (Pubitemid 36348923)
55. Eisenberg, E., McNicol, E., Carr, D.B. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006, 3CD006146.
56. Nicholson, B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003, 63(1): 17-32. (Pubitemid 36132511)
57. Schug, S.A., Zech, D., Grond, S. Adverse effects of systemic opioid analgesics. Drug Saf 1992, 7(3): 200-213
58. Etropolski, M.S., Shapiro, D.Y., Okamoto, A., Rauschkolb-Löffler, C., Lange, R., Häussller, J. Safety and tolerability of tapentadol extended release in patients with painful diabetic peripheral neuropathy: Results of a randomized-withdrawal phase 3 study. Diabetes 2009, 58: A226-A227. Abstract 852-P.
59. Cherny, N.I. Opioid analgesics: Comparative features and prescribing guidelines. Drugs 1996, 51(5): 713-737 (Pubitemid 26147793)
60. Panchal, S.J., Muller-Schwefe, P., Wurzelmann, J.I. Oploid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007, 61(7): 1181-1187 (Pubitemid 46934629)